ERBB2 and breast carcinoma: A significant improvement in survival was recently reported in the treatment of Her2 overexpressing breast cancer patients from combining the antibodies Trastuzumab and Pertuzumab.1 However, the underlying molecular mechanisms have remained enigmatic.